390800-88-1

Basic information

• Product Name: 2-PyrazinecarboxaMide, N,N',N''-[2,4,6-boroxintriyltris[[(1R)-3-Methylbutylidene]iMino[(1S)-2-oxo-1-(phenylMethyl)-2,1-ethanediyl]]]tris-
• Synonyms: 2-PyrazinecarboxaMide, N,N',N''-[2,4,6-boroxintriyltris[[(1R)-3-Methylbutylidene]iMino[(1S)-2-oxo-1-(phenylMethyl)-2,1-ethanediyl]]]tris-;Bortezomib Impurity 10;Bortezomib Trimer;Bortezomib ((1R,2S)-Bortezomib)
• CAS NO: 390800-88-1
• Molecular Formula: C₅₇H₆₉B₃N₁₂O₉
• Molecular Weight: 1098.66576
• EINECS: -0
• Mol File: 390800-88-1.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 1277.7±65.0 °C(Predicted)
• Appearance: /
• Density: 1.26±0.1 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer
• PKA: 11.46±0.46(Predicted)
• CAS DataBase Reference: 2-PyrazinecarboxaMide, N,N',N''-[2,4,6-boroxintriyltris[[(1R)-3-Methylbutylidene]iMino[(1S)-2-oxo-1-(phenylMethyl)-2,1-ethanediyl]]]tris-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-PyrazinecarboxaMide, N,N',N''-[2,4,6-boroxintriyltris[[(1R)-3-Methylbutylidene]iMino[(1S)-2-oxo-1-(phenylMethyl)-2,1-ethanediyl]]]tris-(390800-88-1)
• EPA Substance Registry System: 2-PyrazinecarboxaMide, N,N',N''-[2,4,6-boroxintriyltris[[(1R)-3-Methylbutylidene]iMino[(1S)-2-oxo-1-(phenylMethyl)-2,1-ethanediyl]]]tris-(390800-88-1)

Safety Data

• Hazardous Substances Data: 390800-88-1(Hazardous Substances Data)

Usage

Description

2-Pyrazinecarboxamide, N,N',N''-[2,4,6-boroxintriyltris[[(1R)-3-methylbutylidene]imino[(1S)-2-oxo-1-(phenylmethyl)-2,1-ethanediyl]]]trisis a complex organic compound with a unique structure that features a pyrazinecarboxamide core and a boroxintriyltris backbone. This molecule is characterized by its intricate arrangement of atoms and functional groups, which may contribute to its potential applications in various fields.

Uses

Used in Pharmaceutical Industry:
2-Pyrazinecarboxamide, N,N',N''-[2,4,6-boroxintriyltris[[(1R)-3-methylbutylidene]imino[(1S)-2-oxo-1-(phenylmethyl)-2,1-ethanediyl]]]trisis used as a potential therapeutic agent for the treatment of multiple myeloma, a blood cancer. It functions as a reversible inhibitor of the 26S proteasome, a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. By targeting the ubiquitin-proteasome pathway, this compound can modulate cellular processes and exhibit inhibitory effects on tumor growth and progression.
Used in Drug Delivery Systems:
In the field of drug delivery, 2-Pyrazinecarboxamide, N,N',N''-[2,4,6-boroxintriyltris[[(1R)-3-methylbutylidene]imino[(1S)-2-oxo-1-(phenylmethyl)-2,1-ethanediyl]]]triscan be employed to improve the delivery, bioavailability, and therapeutic outcomes of various pharmaceutical compounds. Its unique structure may allow for the development of novel drug delivery systems, such as organic and metallic nanoparticles, which can enhance the efficacy of the compound in treating specific conditions.

Upstream product

• 205393-22-2 N-[(1S)-1[[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]carbonyl]-2-benzyl]2-pyrazine carboxamide 
• 179324-69-7 velcade 

Downstream Products

• 1201903-00-5 (R)-2-hydroxy-2-((R)-2-((R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl)-5-oxo-1,3,2-dioxaborolan-4-yl)acetic acid 
• 1201903-01-6 (S)-2-hydroxy-2-((S)-2-((R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl)-5-oxo-1,3,2-dioxaborolan-4-yl)acetic acid 
• 1201902-95-5 N-[(1S)-1-benzyl-2-({(1R)-3-methyl-1-[(5R)-4-oxo-5-phenyl-1,3,2-dioxaborolan-2-yl]butyl}amino)-2-oxoethyl]pyrazine-2-carboxamide 
• 1201902-97-7 N-((S)-1-((R)-3-methyl-1-(4-oxo-4H-benzo[d][1,3,2]dioxaborinin-2-yl)butylamino)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxamide 
• 1201902-99-9 2-((R)-2-((R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl)-5-oxo-1,3,2-dioxaborolan-4-yl)acetic acid 

Relevant articles and documents

Process for Preparing and Purifying Bortezomib

The present invention provides a synthetic process for producing bortezomib using a novel intermediate. The present invention also provides a process for purifying bortezomib anhydride, and a new crystalline polymorph of bortezomib anhydride.

METHODS FOR PREPARING BORTEZOMIB AND INTERMEDIATES USED IN ITS MANUFACTURE

Provided herein are methods for preparing bortezomib and intermediates useful in the preparation of bortezomib. The present methods unexpectedly provide superior yields and purities, including optical purities, of bortezomib and the intermediates for the preparation of bortezomib.